JPS61226059A - Adsorbent for anti-deoxyribonucleic acid antibody - Google Patents

Adsorbent for anti-deoxyribonucleic acid antibody

Info

Publication number
JPS61226059A
JPS61226059A JP60068096A JP6809685A JPS61226059A JP S61226059 A JPS61226059 A JP S61226059A JP 60068096 A JP60068096 A JP 60068096A JP 6809685 A JP6809685 A JP 6809685A JP S61226059 A JPS61226059 A JP S61226059A
Authority
JP
Japan
Prior art keywords
adsorbent
dna
adsorption
polymer compound
epoxy group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60068096A
Other languages
Japanese (ja)
Other versions
JPH0126709B2 (en
Inventor
順一 長沢
山内 愛造
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
Agency of Industrial Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology
Priority to JP60068096A priority Critical patent/JPS61226059A/en
Publication of JPS61226059A publication Critical patent/JPS61226059A/en
Publication of JPH0126709B2 publication Critical patent/JPH0126709B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • External Artificial Organs (AREA)

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。
(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 産業上の利用分野 本発明はデオキシリボ核酸(以下DNAと略記する)を
高分子担体に安定した状態で固定して成る抗D N A
抗体用吸着材に関するものである。さらに詳しくいえば
、本発明は、滅菌か゛容易で、かつ選択性が優れる上に
吸着能力が大きく、しかも取扱いか容易であって、全身
性エリテマトーデスなどの自己免疫疾患の要因物質であ
る抗1’) N ノル抗体やD N A−抗D N A
抗1本免疫複合体を、該疾患患者の+fn漿中から除去
するのに好適に用いられる安定性に優れた吸着材に関す
るものである。
[Detailed Description of the Invention] Industrial Application Field The present invention provides an anti-DNA comprising deoxyribonucleic acid (hereinafter abbreviated as DNA) stably immobilized on a polymer carrier.
This invention relates to an adsorbent for antibodies. More specifically, the present invention is easy to sterilize, has excellent selectivity, has a large adsorption capacity, is easy to handle, and has anti-1' ) Nnor antibody or DNA-anti-DNA
The present invention relates to an adsorbent with excellent stability that can be suitably used to remove anti-1 antibody immune complexes from +fn plasma of patients with the disease.

従来の技術 近年、医工学技術の著しい発展に件5・、全身性エリテ
マトーデス、慢性関節リウマチ、強皮症などの自己免疫
疾患の治療には、患者の血液中からこれらの疾患の要因
物質を除去する血液浄化療法か確立されつつある。この
血液浄化療法としては、これまで血漿交換法、ろ過法、
吸着法などが試みられているか、いずれの方法もなんら
かの欠点かあり必ずしも満足しうるちのとはいえなり・
Conventional technology In recent years, with the remarkable development of medical engineering technology, treatment of autoimmune diseases such as systemic lupus erythematosus, chronic rheumatoid arthritis, and scleroderma requires the removal of the causative substances of these diseases from the patient's blood. Blood purification therapy is being established. This blood purification therapy has so far included plasma exchange, filtration,
Adsorption methods have been tried, but all methods have some drawbacks and are not necessarily satisfactory.
.

例えば、血漿交換法は、患者の血漿を新鮮な凍結血漿又
は血漿製剤で置き換える方法であるか、置換液の大量撞
゛保か困t#であり、かつ血性肝炎などの感染の危険性
があるなど、重要な問題を有している。またろ過法とし
ては、で2種のフィルターにより特定の分子量を有する
もののみを分画除去する二重ろ渦状などが試みられてい
るか、十分な分画能を有するフィルターは見出されてお
らず、しかもこの方法は分子サイズによる分画であるた
め、有用物質ら同時に除去されるので、血漿補充液を必
要とするなどのjijJ題があって、まだ実用化に至っ
ていない。−・方吸着法については、吸着材として活性
炭、スチレン−ノビニルベンゼン共重合体、陰イオン交
換樹脂などを用いた!(工肝臓や吸着聖人−][腎臓か
すでに実用化されている。しがしなから、これらの吸着
材は、抗D N A抗体などの比較的高分子窄成分を選
択的に吸着除去する能力を有していない。
For example, plasmapheresis is a method of replacing a patient's plasma with fresh frozen plasma or plasma preparations, or it is difficult to maintain large amounts of replacement fluid, and there is a risk of infection such as bloody hepatitis. There are important issues such as: As for filtration methods, attempts have been made to use two types of filters, such as a double vortex filter that fractionates and removes only substances with specific molecular weights, but no filter with sufficient fractionation ability has been found. Moreover, since this method involves fractionation based on molecular size, useful substances are removed at the same time, and there are problems such as the need for plasma replenishment fluid, so it has not yet been put to practical use. - Method For the adsorption method, activated carbon, styrene-novinylbenzene copolymer, anion exchange resin, etc. were used as the adsorbent! (Engineering liver and adsorbent saints) [Kidneys have already been put into practical use.However, these adsorbents selectively adsorb and remove relatively high-molecular components such as anti-DNA antibodies. does not have the ability.

これらの方法の中で、血液中の疾患要因物質を除去する
には、吸着法が種々の点で右利であり、そのため、特定
の疾患要因物質のみを吸着除去しうる吸着+4の開発か
望まれている。
Among these methods, the adsorption method is advantageous in various respects for removing disease-causing substances from the blood. Therefore, it is desirable to develop adsorption +4, which can adsorb and remove only specific disease-causing substances. It is rare.

ところで、生化学分野においては、抗原−抗体、酵素−
基質、酵素−1!11害剤、ホルモン−レセプターなど
、それぞれの物質量だけに存在する特pJ的な川原作用
を利用して、特定タンパク質成分を分離ネ!’i 製’
1−る手法、すなわもアフィニティクロマトグラフィー
か広く用いられている1、このアフィニティクロマトグ
ラフィーに用いる吸着イ・(は、目的物質と親和・l’
lを有する物質を担体に固定、ト溶化した乙ので゛ある
By the way, in the field of biochemistry, antigen-antibody, enzyme-
Separate specific protein components such as substrates, enzyme-1!11 harmful agents, hormone receptors, etc. by utilizing the special pJ-like Kawahara action that exists only in the amount of each substance! 'Made by i'
The adsorption method used in affinity chromatography is the affinity chromatography method used in affinity chromatography.
This is a method in which a substance having 1 is immobilized on a carrier and dissolved.

このようなアフィニティクロマトグラフィーの原理を応
用し、血液中の抗1’) N A抗体などの免疫物質を
除去するのに、該免疫物質と特異的に免疫反応する物質
を利用する研究か積極的に行われている。例えば、全身
性エリテマト−デ゛又に関しては、吸着1象物質として
、抗D NA抗困やI−) N A −抗り1寸、X抗
体免疫複合14(が考えられ、これらに対する吸着利と
して、(1)メチル化アルブミンを多糖類ゲル粒子に固
定したもの(特開昭55−120875号公報)、(2
)セルロースに1吸着させた1)NAを寒天ゲルで包括
したらの〔[クリニカル・アンド・イクスペリメンタル
・イミュノロノー(CIin。
Applying the principle of affinity chromatography, we are actively researching the use of substances that specifically react with immune substances to remove immune substances such as anti-1'NA antibodies from the blood. is being carried out. For example, with regard to systemic lupus erythematosus, the adsorbent substances are anti-DNA anti-I, anti-I-) NA-anti-1, and X-antibody immune complex 14. , (1) Methylated albumin immobilized on polysaccharide gel particles (JP-A-55-120875), (2
) When 1) NA adsorbed on cellulose was encapsulated in agar gel [[Clinical and Experimental Immunology (CIin.

hl〕、 l+nmuno1.)l第2.・1巻、第2
31−237ペーン(1976イ1′)〕、(3)活性
炭に吸着させたD N Aをフロンオンで包括したもの
〔[クリニカル・イミュノロジー・アンド・イミュノパ
ソロンー(CIin。
hl], l+nmuno1. ) l 2nd.・Volume 1, Volume 2
31-237 Penn (1976 1')], (3) DNA adsorbed on activated carbon and encapsulated with Freon [[Clinical Immunology and Immunopathy (CIin.

11111111111O1,1mmunopalho
1.)l第8巻、 第9 (’l −96ページ(19
77年)〕、(,1) I’) N Aと二価金属イオ
ンとの複合1本〔「ジャーナル・オフパ・イミュノロジ
カル・メソッズ(,1,rvnunol、 lイe t
: l+ o d s月第′イ()巻1第89−9.1
ページ(1981年)〕、(5)DNAを高分子コラー
ゲン膜にアシルアットで共有結合したもの〔[バイオテ
クノロジ゛−・アンド・バイオエンジニアリング(li
iot、ecl+no1. Bioeng、 )I第2
6巻、第665〜669ページ(]9984年〕などが
tri案されている。
11111111111O1,1mmunopalho
1. )l Volume 8, No. 9 ('l -page 96 (19
1977)], (,1) I') One complex of NA and divalent metal ions [Journal Offa Immunological Methods
: l+ o d s Month 1'i () Volume 1 No. 89-9.1
Page (1981)], (5) DNA covalently bonded to a polymeric collagen membrane with acylat [[Biotechnology and Bioengineering (LI)].
iot, ecl+no1. Bioeng, ) I 2nd
Volume 6, pages 665-669 (9984), etc. have been proposed.

このような生体高分子を固定化した吸着材においては、
滅菌時、あるいは保存中や使用中における安定性に優れ
ていることが必要であり、特に使用時において固定化し
たD N Aやたんばく質が゛1111液中に溶出する
と重大な副作用が生じるI3それがある。したがって、
生体高分子を吸着材に利用する場合は、できるだけ強固
に固定化する必要がある。
In adsorbents with immobilized biopolymers,
It is necessary to have excellent stability during sterilization, storage, and use, and especially during use, if immobilized DNA or protein is eluted into the 1111 solution, serious side effects may occur. There is that. therefore,
When using biopolymers as adsorbents, it is necessary to immobilize them as strongly as possible.

しかしなから、前記の吸着材においては、固定化物の安
定性に−〕いて必ずしも満足しうるちのではなく、また
いずれも滅菌の手段か゛不明であって、実用上の問題か
ある。
However, the above-mentioned adsorbents are not always satisfactory in terms of the stability of the immobilized material, and the means for sterilization is unclear, which poses a practical problem.

発明か解決しようとする問題点 本発明の目的は、このようなイ(情のもとで、1゛I走
菌が容易で、か−゛)選択性か優れる十に吸着能力が大
きく、しかも取扱いが容易であって、全身性エリテマト
ーデスなどの自己免疫疾患の要因物質である抗1)N 
A抗体やl) N A−抗r) N A抗体免疫複合体
を、該疾患患者の血漿中から除去するのに好適に用いら
れる安定性に優れた吸着4(4を提供することにある。
Problems to be Solved by the Invention The object of the present invention is to obtain a microorganism that has excellent selectivity, excellent adsorption capacity, and Anti-1)N is easy to handle and is a factor in autoimmune diseases such as systemic lupus erythematosus.
An object of the present invention is to provide an adsorption agent 4 (4) with excellent stability that can be suitably used to remove A antibody and l)NA-anti-r)NA antibody immune complex from the plasma of patients with the disease.

問題点を解決するための手段 本発明者らは鋭意研究を重ねた結果、エポキシ基と結合
しうる官能基を有する高分子化合物を担体として用い、
これにエポキシ基を導入し、該エポキシ基を介してD 
N Aを化学結合させたらのかriij記1」的に適合
しうろことを見出し1、二の知見に基づいて本発明を完
成するに至った。
Means for Solving the Problems As a result of extensive research, the present inventors found that using a polymer compound having a functional group capable of bonding with an epoxy group as a carrier,
An epoxy group is introduced into this, and D
The present invention was completed based on the findings 1 and 2 of the present invention by discovering scales that are compatible with chemical bonding of NA.

すなわち、本発明は、エポキシ基を導入した高分子化合
物に、該エポキシ基を介してl’、) N Aを化学結
合させて成る抗1’) N A抗体用吸着材を提0(す
るものである。
That is, the present invention provides an adsorbent for anti-1')NA antibodies, which is formed by chemically bonding l',)NA to a polymer compound into which an epoxy group has been introduced via the epoxy group. It is.

これまで゛、エポキシ基を介してl) N Aを担体に
固定化する方法は、たんばく質などの精製のために、ア
フィニテイクロマ)・グラフィー用吸着剤に用いられた
例はあるか、血漿浄化用吸着剤に適用された例はない。
Has the method of immobilizing NA on a carrier via an epoxy group been used in affinity chromatography adsorbents for the purification of proteins? There are no examples of it being applied to adsorbents for plasma purification.

本発明においては、担体としこエポキシ基を導入しうる
ような官能基、例えば水酸基やチオール基を有する高分
子化合物が用いられるか、非特異的な吸着能をもたない
非イオン性物質か望よい)。
In the present invention, it is preferable to use a polymer compound having a functional group, such as a hydroxyl group or a thiol group, into which an epoxy group can be introduced as a carrier, or a nonionic material that does not have nonspecific adsorption ability. ).

このようなものとしては、例えばアガロース系、デ゛キ
ス1ラン系、セルロース系、ポリビニルアルコール系な
どの水酸基含有高分子化合物か好適である3、また、担
体の形状については、表面積が大きいものであれば特に
制限はなく、例えばビーズ状、繊維状、中空糸状などの
形状を有するものか用いられる。
For example, hydroxyl group-containing polymer compounds such as agarose, Dekis 1 run, cellulose, and polyvinyl alcohol are suitable as such carriers. There are no particular limitations, and for example, those having a bead-like, fibrous, or hollow fiber-like shape may be used.

前記高分子化合物にエポキシ基を導入する方法としでは
、アルカリ性条件下でエピクロロヒドリンや、1,11
−ビア、(2+:(−エポキシプロポキン)7タンのよ
うなビスオキシラン化合物などを作用させる公知の方法
の中から汀意のJj法を用いる、二とかて゛ぎ る。
As a method for introducing epoxy groups into the polymer compound, epichlorohydrin, 1,11
-Via, (2+:(-epoxypropoquine)7) Among the known methods of acting with a bisoxirane compound such as (2+:(-epoxypropoquine)7tan), there are two methods using the arbitrary Jj method.

次に、エポキシ7Jζが導入された高分子化合物に、該
エポキシ丸!−を介してD N Aを化合結合させるた
めには、例えばpfl !]−13、好ましくはH)、
5〜12のアルカリ性水溶液中におい′乙該エポキシ基
導入高分子化合物と所望のr) N Aとを、3()・
−80°C1好士しくは1. fl −G fi ’C
の261度に保ちなから所要時間反応させれば」:い。
Next, the epoxy 7Jζ was introduced into the polymer compound. - For example, pfl! ]-13, preferably H),
In an alkaline aqueous solution of 5 to 12, the epoxy group-introduced polymer compound and the desired 3().
-80°C1 preferably 1. fl -G fi 'C
Just keep it at 261 degrees and let it react for the required time.'': Yes.

温度か代すぎると反応速度か遅く、か−)加熱した際の
固定化1)N Aの1−分な安定41′1か゛イ:1ら
れず、−ノj高すぎると1”’) N Aの固定化1j
)、が減少する。また反応時間は’(A+’+度に1っ
て左右されるか、通常5 = 4. (’1時間程度で
・よい1、さらに、高分子化合物に月するl’) N 
Aの(旧よ1、該高分子化合物に導入されたエポキシJ
1(の1武によって適宜選ばれ、またその濃度は高い方
か固定化1j)か多くなる。
If the temperature is too high, the reaction rate will be slow, or -) Immobilization when heated 1) Stability at 1 minute of N Immobilization of A 1j
), decreases. In addition, the reaction time depends on '(A +' + 1 degree), usually 5 = 4. ('1 hour is good, and it takes about 1 hour for the polymer compound.') N
A (formerly 1, epoxy J introduced into the polymer compound)
1 (of 1) is selected as appropriate, and its concentration is higher or immobilized 1j) or more.

このようにしてD N Aか固定化された高分子化合物
をろ刷上 1−分に洗浄することにより、本発明の1吸
着祠が得られる。
By washing the polymer compound with immobilized DNA on the filter for 1 minute, an adsorption column of the present invention can be obtained.

発明の効果 本発明の吸着イ・利よ、従来のものと異なりD NAか
エポキシ基を発して担体の高分子化合物に(板めて安定
に結合しており、例えばD N Aの脱落は・1°Cの
温度で70 B l用保存した場合は・・1%以下、8
0°Cで1時間熱処理した場合は2%以下であるように
僅かであり、また抗D N A抗体に月する吸着活性も
保存や熱処理によって損われなり)など、優れた特徴を
有している。
Effects of the Invention Unlike conventional adsorption methods, DNA or epoxy groups are released and bonded stably to the polymer compound of the carrier. When stored at a temperature of 1°C for 70 Bl...1% or less, 8
It has excellent characteristics, such as the amount of adsorption is only 2% or less when heat treated at 0°C for 1 hour, and the adsorption activity for anti-DNA antibodies is not impaired by storage or heat treatment. There is.

さらに、エポキシ基は安定なエーテル結合やチオエーテ
ル結合を介して担体に導入されてし)るので、該エポキ
シ基の脱落のおそれはなく、その上エポキシ基の導入の
際に担体の架橋が同時に起こるので、該担体は強固とな
り、加熱などに対して安定性に優れたものとなる。した
がって、滅菌方法としては、簡便な加熱方法を適用する
ことかできる。
Furthermore, since the epoxy group is introduced into the carrier via a stable ether bond or thioether bond, there is no risk of the epoxy group falling off, and furthermore, crosslinking of the carrier occurs simultaneously when the epoxy group is introduced. Therefore, the carrier becomes strong and has excellent stability against heating and the like. Therefore, a simple heating method can be applied as a sterilization method.

このように本発明の吸着材は安定性に没れ、かつその製
造や滅菌が容易である−1−に、選択性能や吸着性能に
ついては従来のものと比較し一ζ遜色かなく、例えば全
身性エリテマトーデスなとの自己免疫疾患の血液浄化療
法として、その要因物質である抗1) N A抗体やD
 N A−抗I)N A抗体免疫複合本を該疾患思考の
血漿中から除去するのに好適に用いられる。。
As described above, the adsorbent of the present invention has excellent stability and is easy to manufacture and sterilize.In addition, its selectivity and adsorption performance are comparable to those of conventional ones. As blood purification therapy for autoimmune diseases such as sexual lupus erythematosus, anti-1) NA antibodies and D
NA-Anti-I) NA antibody immune complexes are suitably used to remove from the plasma of the disease. .

実権例 次に実施例により本発明をさらに詳細に説明する。example of real power Next, the present invention will be explained in more detail with reference to Examples.

実施例1 セファローズ、′口I (ファルマシア利製)をエビク
ロロヒドリン処理して得られた、水分95.6重(i(
%、エポキシ基導入喰8 り lOmo l / g乾
燥ビーズのビーズ5gと、サケ楯液山米のD N A 
[和光純薬玉業(株)製〕を0.5M炭酸ナトリウム−
水酸化すl・リウム(モル比’7 : 、E )水溶液
に溶かした、l)N Ai農度4.7重量%、pH10
,7の溶液1 f−1rIρとをiiRイγし1.1 
il ’Cで2.1時間振とうした。次いで、ピースを
0.1ぺ抽1酸lJ&t!IIj液(pl+4.0)及
び0 、2 M炭酸紙jΦj液(++I19.0)で゛
繰り返し洗浄後、0.1八4ホウ酸緩イ千J液(pH7
,3)、1M塩化す1す・クム溶液及び蒸留水で洗浄し
て、D N Aを固定化したビーズ状吸着材を111だ
Example 1 Sepharose, I (manufactured by Pharmaciali) was treated with shrimp chlorohydrin.
%, epoxy group-introduced food 8 mol/g 5 g of dried beads and the DNA of salmon shield liquid mountain rice
0.5M sodium carbonate [manufactured by Wako Pure Chemical Industries, Ltd.]
Lithium hydroxide (molar ratio '7:, E) dissolved in aqueous solution, N Ai concentration 4.7% by weight, pH 10
, 7 solution 1 f-1rIρ and iiR iγ and 1.1
Shake for 2.1 hours at il'C. Next, the pieces were extracted with 0.1 pe 1 acid lJ&t! After repeated washing with IIj solution (pl+4.0) and 0,2 M carbonated paper jΦj solution (++I19.0), 0.184 boric acid mild 1,000 J solution (pH 7)
, 3), 111 is a bead-like adsorbent on which DNA is immobilized by washing with a 1M sodium chloride solution and distilled water.

このもののDNAの含有量を、モリブデンブルー法によ
るリンの測定より求めたところIl’i、燥吸着441
 g当り23Il!gであった。
The DNA content of this product was determined by measuring phosphorus using the molybdenum blue method.Il'i, dry adsorption 441
23Il per g! It was g.

次に、このようにして得られた吸着ヰJ’1.5g(乾
燥重量87目)に0.01Mホウ酸緩衝液−生理食塩水
(pH7,5:l 1F)mpを加え、8 (1’Cで
1時間振とうした。処理後、溶液の2 Of’l nR
における吸光度測定及び吸着材中のリンの測定により、
D N Aの脱落率を求めたところ、1.8%であった
。なお、吸着Hの形状は熱処理後も変化が認められなか
った。
Next, 0.01 M borate buffer-physiological saline (pH 7.5:l 1F) mp was added to 1.5 g (dry weight 87) of the adsorbed J' obtained in this way, and 8 (1 After the treatment, the solution was shaken for 1 h at
By measuring the absorbance in and measuring the phosphorus in the adsorbent,
The DNA dropout rate was determined to be 1.8%. Note that no change in the shape of adsorbed H was observed even after heat treatment.

実施例2 実施例1と同様にして作成した、D N A鯖介量間保
存後、1M塩化ナトリウム溶液及び蒸留水で洗浄した。
Example 2 DNA mackerel prepared in the same manner as in Example 1 was stored for a while and then washed with 1M sodium chloride solution and distilled water.

このもののD N A含有量は乾燥吸着材1g当りI 
、’+ fl thgて゛あった。
The DNA content of this product is I per gram of dry adsorbent.
,'+ fl thg was there.

実施例3 トヨパールINV  (i 5 〔東洋曹達1゜業(株
)製〕を1.4−ビス(2,:(−エポキシプロポキシ
)フタンで処理して1:1られた、水分89.6’i’
ji%、エボキシノ、(導入1往0.19vno l 
/ y乾1.%i、ピース゛のビーズ5yと、「)Nノ
ル濃度5.1重h196.1+1IIl、)!の→Jケ
lII□液111来の1’、) N A溶液10岬とを
;15合し、実施例1と同様に処理して、D N Aを
固定化したビーズ状吸着月を得た。このもののD N 
A含有1廿は轄1へI・I汲オ’f4・41 g当り5
〃9で゛あった。
Example 3 Toyopearl INV (i5 [manufactured by Toyo Soda 1゜Gyo Co., Ltd.] was treated with 1,4-bis(2,:-epoxypropoxy)phthane to give a 1:1 ratio, and the moisture content was 89.6'. i'
ji%, Eboxino, (Introduction 1 time 0.19 vno l
/ y dry 1. %i, piece 5y of beads and 15% of N concentration 5.1 heavy h196.1 + 1IIl,)! → J Kel II The same treatment as in Example 1 was carried out to obtain bead-like adsorbed particles with immobilized DNA.
1 unit containing A is transferred to Category 1.
It was 9.

実施例3・1 エピクロロヒドリンで゛処理した、エポキシ基導入計0
.06mロ+ol/g乾燥ガーゼのガーゼ1.29に、
rlNA濃度5.2重け%、1+II]1.2のサケ精
液由来のD N A溶液20m0を加え、実施例1と同
様に処理して、D N Aを固定化した吸着材をイ)ま
た。このムののD N A含有量は、乾1・v・吸着材
1g当り3躍9であった。
Example 3.1 Epoxy group introduction meter treated with epichlorohydrin 0
.. Gauze 1.29 of 06ml + ol/g dry gauze,
20 m0 of a salmon semen-derived DNA solution with rlNA concentration of 5.2% by weight and 1 . The DNA content of this product was 3.9% per 1g of dry 1.v adsorbent.

実施例5 エビクロロヒドリンで処理した、エポキシ基導入量0.
07+0+nol/ g乾燥繊維の細繊化ポリビニルア
ルコール繊維1.0gに、D N A濃度5.1重量%
、1〕1111.3のサケ精液製D N A溶液207
1ρを加え、実施例1と同様に処理して、DNAを固定
化した吸着4・Aを得た。このもののD N A含有量
は、乾燥吸着材1g当りSIngで゛あった。
Example 5 Shrimp treated with chlorohydrin, the amount of epoxy group introduced was 0.
07+0+nol/g dry fiber, finely divided polyvinyl alcohol fiber 1.0g, DNA concentration 5.1% by weight
, 1] Salmon semen DNA solution 207 of 1111.3
1ρ was added and treated in the same manner as in Example 1 to obtain adsorbed 4·A on which DNA was immobilized. The DNA content of this product was SIng per gram of dry adsorbent.

実施例6 担体としてセファローズ、4.8を用い、実施例1と同
様に処理して得られた水分含量92.7重量%のビーズ
状吸着材5(Ji9(DNA含有量0.7hy)を、0
.0gMリン酸緩衝液−十理食塩水(pH7,3、以下
PBSと略記する)で洗浄後、このものと、全身+Lエ
リテマトーデス患者の血清250μpとを混合し、1時
間振とうした。
Example 6 Using Sepharose 4.8 as a carrier, bead-like adsorbent 5 (Ji9 (DNA content 0.7hy) with a water content of 92.7% by weight obtained by the same treatment as in Example 1) was used. ,0
.. After washing with 0 gM phosphate buffer-saline (pH 7.3, hereinafter abbreviated as PBS), this was mixed with 250 μp of serum from a whole body + L lupus erythematosus patient and shaken for 1 hour.

処理前後の血清をPBSで倍々に希釈した系列を作り、
抗ネイティブDNAh+DNA)抗体を、抗n D N
 A抗体テストキット(カレスタツド社製)を用いてけ
い光抗体法で測定し、陰性になる希釈倍率を求めた。そ
の結果を次表に示す。
Create a series of diluted serum before and after treatment with PBS,
Anti-native DNAh+DNA) antibody, anti-nDN
Measurement was carried out by a fluorescent antibody method using an A antibody test kit (manufactured by Kalestad), and the dilution ratio at which the result was negative was determined. The results are shown in the table below.

参考例 担体としてセファローズ4Bを用い、実施例1と同様に
処理して得られた水分含量94.1重量%のビーズ状吸
着材50 f’l mg(1’) N A含有量4.5
6〜)をPBSで洗浄後、このものと、牛血清アルブミ
ン及びγ−グロブリンそれぞれ1()ηgをF’ B 
S ] (’1ytrlに溶かした液とを混合上 25
°Cで1時間振とうしたのも、[J v吸収により牛血
清アルブミン及びγ−グロブリンの吸着をそれぞれ調べ
たが、いすれの場合ら吸着は認められなかった。
Reference Example A bead-like adsorbent with a water content of 94.1% by weight obtained by using Sepharose 4B as a carrier and treated in the same manner as in Example 1. 50 f'l mg (1') NA content 4.5
After washing 6~) with PBS, 1()ηg each of bovine serum albumin and γ-globulin were added to F'B.
S ] (Mix with the solution dissolved in '1ytrl 25
After shaking at °C for 1 hour, adsorption of bovine serum albumin and γ-globulin was examined by Jv absorption, but no adsorption was observed in either case.

Claims (1)

【特許請求の範囲】 1 エポキシ基を導入した高分子化合物に、該エポキシ
基を介してデオキシリボ核酸を化学結合させて成る抗デ
オキシリボ核酸抗体用吸着材。 2 高分子化合物が水酸基を含有するものである特許請
求の範囲第1項記載の吸着材。 3 水酸基を含有する高分子化合物がアガロース系、デ
キストラン系、セルロース系又はポリビニルアルコール
系化合物である特許請求の範囲第2項記載の吸着材。
[Scope of Claims] 1. An adsorbent for anti-deoxyribonucleic acid antibodies, which is formed by chemically bonding deoxyribonucleic acid to a polymer compound into which an epoxy group has been introduced via the epoxy group. 2. The adsorbent according to claim 1, wherein the polymer compound contains a hydroxyl group. 3. The adsorbent according to claim 2, wherein the hydroxyl group-containing polymer compound is an agarose-based, dextran-based, cellulose-based, or polyvinyl alcohol-based compound.
JP60068096A 1985-03-30 1985-03-30 Adsorbent for anti-deoxyribonucleic acid antibody Granted JPS61226059A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60068096A JPS61226059A (en) 1985-03-30 1985-03-30 Adsorbent for anti-deoxyribonucleic acid antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60068096A JPS61226059A (en) 1985-03-30 1985-03-30 Adsorbent for anti-deoxyribonucleic acid antibody

Publications (2)

Publication Number Publication Date
JPS61226059A true JPS61226059A (en) 1986-10-07
JPH0126709B2 JPH0126709B2 (en) 1989-05-25

Family

ID=13363861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60068096A Granted JPS61226059A (en) 1985-03-30 1985-03-30 Adsorbent for anti-deoxyribonucleic acid antibody

Country Status (1)

Country Link
JP (1) JPS61226059A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020114A1 (en) * 1998-10-06 2000-04-13 Bioprocessing Ltd. Adsorbent medium and its use in purifying dna
US7695910B2 (en) 2001-09-01 2010-04-13 Samsung Electronics Co., Ltd. Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020114A1 (en) * 1998-10-06 2000-04-13 Bioprocessing Ltd. Adsorbent medium and its use in purifying dna
US6723539B1 (en) 1998-10-06 2004-04-20 Bioprocessing, Ltd. Absorbent medium containing particles of chopped cellulose or agarose sponge material having functional groups
US7695910B2 (en) 2001-09-01 2010-04-13 Samsung Electronics Co., Ltd. Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group

Also Published As

Publication number Publication date
JPH0126709B2 (en) 1989-05-25

Similar Documents

Publication Publication Date Title
US4576928A (en) Adsorbent and process for preparing the same
CN102361689A (en) Sorbent for endotoxins
JPH0144725B2 (en)
JPH0724723B2 (en) Sulfated non-carbohydrate Germantrics adsorbent
CN1327901C (en) Endotoxin-binding ligands and their use
JPS61226059A (en) Adsorbent for anti-deoxyribonucleic acid antibody
CA1283073C (en) Adsorbent for purification of blood coagulation factor viii and process for purification of blood coagulation factor viii using the same
JPS59193135A (en) Adsorbing body
JPH0622633B2 (en) Adsorbent and removal device using the same
JPS62192172A (en) Adsorbing body
JPS5812656A (en) Adsorbing material for treating recirculation
JPH01181875A (en) Adsorptive body of immune complex and removing device for immune complex with it
JPS6253669A (en) Material and apparatus for adsorbing immunoglobulin substance
JP2726662B2 (en) Adsorbent and removal device using the same
JPS6226073A (en) Method and apparatus for direct infusion and adsorption of blood
JPH0771632B2 (en) Adsorbent and removal device using the same
JPS58165860A (en) Carrier of adsorbing material for purifying body liquid
JP3251547B2 (en) Immune complex removal device
JPS63132665A (en) Apparatus for recovery of protein in blood
JP3084436B2 (en) Anti-DNA antibody removal device
Sato et al. Effect of pore size of porous bead carriers immobilizing antibody on IgE adsorption
JPH04227268A (en) Manufacture of adsorbing body
JPH05176994A (en) Low specific gravity lipoprotein adsorbent
JPS6077769A (en) Production of adsorbing body
JPH0134067B2 (en)

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term